Efficacy and Safety of Curcumin as an Adjuvant to Standard Chemotherapy in Advanced and Metastatic Breast Cancer Patients: A Randomized Controlled Study.
- 2025-09-03
- RCT · n = 120
- Phytotherapy research : PTR 39(11)
- Shekhar Goyal
- Surender K Beniwal
- Pallavi Agarwal
- Rajnish K Brar
- Priyanka Jain
- H S Kumar
- Bhudev C Das
- PubMed: 40898993
- DOI: 10.1002/ptr.70086
- High evidence
- Large Human Trial
- Clinical
ORR was significantly higher in the curcumin group than in those who received standard chemotherapy (38.33% vs. 8.33%, p < 0.01) at 4 weeks follow-up post-treatment, which further improved (43.40% vs. 10.64%, p < 0.0031) upon completion of 12 weeks post-treatment.
- Effect
- Beneficial
- Effect size
- Large
- Significant
- Yes
- Dose
- 500 mg capsule (1 g/day) containing 95% curcuminoid and 1% piperine